Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Aethlon Medical Inc AEMD

Aethlon Medical, Inc. is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. The Hemopurifier, in pre-clinical studies, has demonstrated the removal of harmful exosomes from biological fluids, utilizing its lectin-based... see more

Recent & Breaking News (NDAQ:AEMD)

Aethlon Medical Announces Issuance Of Exosome Capture Patent

PR Newswire June 14, 2016

Aethlon Medical To Present Cancer And Infectious Disease Initiatives, As Well As Chronic Traumatic Encephalopathy (CTE) Candidate Biomarker Discovery At Tomorrow's BIO International Convention

PR Newswire June 6, 2016

Aethlon Medical To Present At 2nd Annual Sachs Associates Immuno-oncology: BD&L And Investment Forum On June 3, 2016

PR Newswire June 1, 2016

Aethlon Medical's CEO and Executive Chairman James Joyce Interviewed by The Life Sciences Report

Marketwired May 5, 2016

Aethlon Medical's Exosome Sciences Announces Production of ELLSA Exosome Isolation Platform

PR Newswire May 4, 2016

Aethlon Medical (AEMD) CEO Note: Hemopurifier Clinical Progression, USA Today on the Next Zika, Combating Bioterror & Pandemic Threats

PR Newswire May 2, 2016

FinancialBuzz.com Exclusive NASDAQ MarketSite Interview with Aethlon Medical, Inc. CEO James Joyce

PR Newswire April 5, 2016

Aethlon Medical Discloses Hemopurifier® Clinical Trial and Manufacturing Advancements

PR Newswire March 31, 2016

Aethlon Medical, Inc. Reports Annual Meeting Results

PR Newswire March 30, 2016

Aethlon Medical To Present At Roth Capital Partners 28th Annual Growth Stock Conference On March 16, 2016

PR Newswire March 9, 2016

Aethlon Medical's Exosome Sciences Announces the Publication of Preliminary Findings of a Blood Test to Detect Chronic Traumatic Encephalopathy (CTE) During Life

PR Newswire February 25, 2016

Aethlon Medical To Present At 4th Annual Sachs Cancer Bio Partnering & Investment Forum On February 24, 2016

PR Newswire February 18, 2016

Aethlon Medical to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on February 10, 2016

PR Newswire February 5, 2016

Aethlon Medical Announces Fiscal 2016 Third Quarter Results

PR Newswire February 4, 2016

Aethlon Medical Announces Dengue Virus Study Approval, Chikungunya Virus Capture Data and Completion of U.S. Principal Investigator Training

PR Newswire February 3, 2016

Aethlon Medical to Present at the 18th Annual BIO CEO & Investor Conference

PR Newswire February 1, 2016

Aethlon Medical To Host Third Quarter Fiscal 2016 Investor Call on February 4, 2016

PR Newswire January 29, 2016

Aethlon Medical's Exosome Sciences To Participate In Clinical Research Study To Diagnose Chronic Traumatic Encephalopathy (CTE)

PR Newswire January 12, 2016

Four Companies Involved in the Diagnosis, Treatment, and Prevention of CTE

ACCESS Newswire January 5, 2016

Aethlon Medical's CEO Jim Joyce Interviewed by The Life Sciences Report

Marketwired December 23, 2015